Scholars Central

Research articlePublished 14 Jul 2016

Quality-adjusted survival as an end point in breast cancer trials

Authors: AJ Martin, RJ Simes

Clinical Investigation

Volume 3 · Issue 6 · Pages 545

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Breast cancer treatment recommendations will often require an appraisal of likely benefits in relation to likely side effects on survival and quality of life end points, and possibly also an evaluation of the size of the anticipated net clinical benefit against financial costs. Quality-adjusted survival (QAS) analysis methods provide a formal approach for deriving an estimate of net clinical benefit to facilitate this appraisal process. QAS analysis methods have been applied in trials with breast cancer patients of adjuvant therapies as well as treatments for advanced/metastatic disease. QAS analyses based solely on trial data may fail to capture plausible longer-term benefits; thus, methods to explore the possible outcomes of treatment beyond the limits of trial data have been developed. These modeling approaches can help researchers gain insights and identify future research priorities, but do not replace the need for long-term evidence from randomized trials.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Investigation
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “AJ Martin”
  • BylineArticles whose byline prints “RJ Simes”